Arvinas CMO Noah Berkowitz to depart July 3, 2026; severance includes accelerated RSU vesting

ARVINAS, INC.

Dr. Berkowitz will leave as CMO effective July 3, 2026, to pursue other opportunities.
Company has begun a search for a new chief medical officer.
Separation agreement provides 9 months base salary, health coverage, and accelerated vesting of RSUs vesting on or before May 9, 2027.
All other unvested RSUs will be forfeited.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Noah Berkowitz

chief medical officer

ARVN · ARVINAS, INC.

Effective: 2026-07-03
Filed: June 22, 2026, 4:10 PM ET

On June 22, 2026, Arvinas, Inc., a Delaware corporation (the “Company”), and Noah Berkowitz, M.D., Ph.D., the Company’s chief medical officer, agreed that Dr. Berkowitz would depart from his employment with the Company, effective July 3, 2026 (the “Departure”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Noah Berkowitz departed as chief medical officer at ARVINAS, INC..

Action: departed
Role: chief medical officer

Exact text from the filing

On June 22, 2026, Arvinas, Inc., a Delaware corporation (the “Company”), and Noah Berkowitz, M.D., Ph.D., the Company’s chief medical officer, agreed that Dr. Berkowitz would depart from his employment with the Company, effective July 3, 2026 (the “Departure”).

View on SEC.gov

ARVINAS, INC. filing history →

Source: SEC EDGAR

accession 0001628280-26-044627

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.